Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $37.2 million.

  • Intellia Therapeutics' Net Cash Flow rose 45944.56% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 25621.96%. This contributed to the annual value of -$37.6 million for FY2024, which is 8727.05% up from last year.
  • Intellia Therapeutics' Net Cash Flow amounted to $37.2 million in Q3 2025, which was up 45944.56% from $21.9 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Net Cash Flow registered a high of $385.7 million during Q4 2022, and its lowest value of -$229.4 million during Q1 2023.
  • Over the past 5 years, Intellia Therapeutics' median Net Cash Flow value was -$6.9 million (recorded in 2022), while the average stood at $2.2 million.
  • Per our database at Business Quant, Intellia Therapeutics' Net Cash Flow crashed by 162984.93% in 2023 and then skyrocketed by 45944.56% in 2025.
  • Intellia Therapeutics' Net Cash Flow (Quarter) stood at -$211.5 million in 2021, then surged by 282.4% to $385.7 million in 2022, then crashed by 84.61% to $59.4 million in 2023, then increased by 15.7% to $68.7 million in 2024, then plummeted by 45.82% to $37.2 million in 2025.
  • Its last three reported values are $37.2 million in Q3 2025, $21.9 million for Q2 2025, and -$54.6 million during Q1 2025.